Tuberculosis: 9. Treatment

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 4, 1999, Pages 405-411

  Hershfield, Earl ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GESTAGEN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMATE; RIFAMPICIN; RIFAPENTINE; RIFATER; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPARFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; CLINICAL TRIAL; CROSS RESISTANCE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; FLU LIKE SYNDROME; GOUT; HEPATITIS; HUMAN; HYPERURICOSURIA; IMMUNOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MENTAL DISEASE; NEUROLOGIC DISEASE; OPTIC NERVE DISEASE; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TINNITUS; TREATMENT PLANNING; TUBERCULOSIS; VERTIGO; VESTIBULAR DISORDER;

EID: 0033600595     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. 1. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
2. 2. Grosset J. The sterilizing value of rifampicin and pyramide in experimental short course chemotherapy. Tubercle 1978;59:287-97.
3. 3. East African/British Medical Research Council Study. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977;115:3-8.
4. 4. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:579-85.
5. 5. British Thoracic Society and Tuberculosis Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Am Rev Respir Dis 1982;126:460-2.
6. 6. Snider DF, Rogowski J, Zierski M, Bek E, Long MW. Successful intermittent treatment of smear-positive pulmonary tuberculosis in 6 months: a cooperative study in Poland. Am Rev Respir Dis 1982;125:265-7.
7. 7. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958;39:269-74.
8. 8. Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979;76(Suppl):741-3.
9. 9. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-5.
10. 10. Fox W. Self administration of medicaments. A review of published work and a study of the problems. Bull Int Union Tuberc 1961;31:307-31.
11. 11. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 1964;31:247-71.
12. 12. D'Espo ND. Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis 1982;125:85-93.
13. 13. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis 1987;136:697-8.
14. 14. Tuberculosis Chemotherapy Centre, Madras. Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. BMJ 1973;2:7-11.
15. 15. Hong Kong Chest Service/British Medical Research Council. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle 1976;57:81-95.
16. 16. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: the results up to 30 months. Am Rev Respir Dis 1977;115:727-35.
17. 17. Tuberculosis Committee, Canadian Thoracic Society. Essentials of tuberculosis control for the practising physician. CMAJ 1994;150:1561-71.
18. 18. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149;1359-74.
19. 19. Severe isoniazid-associated hepatitis - New York, 1991-1993. MMWR 1993;42:545-7.
20. 20. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989;140:700-5.
21. 21. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis. A U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
22. 22. Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191-6.
23. 23. Smith CK, Durack DT. Isoniazid and reaction to cheese. Ann Intern Med 1978;88:520-1.
24. 24. Rothfield NF, Bierer MF, Garfield JW. Isoniazid induction of antinuclear antibodies. Ann Intern Med 1978;88:650-2.
25. 25. Girling DJ. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother 1977;3:115-32.
26. 26. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992;152:711-6.
27. 27. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(RR-20):1-58.
28. 28. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353(9167):1843-7.
29. 29. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988;94:842-4.
30. 30. Trébueq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997;1:12-5.
31. 31. Varughese A, Brater DC, Benet LZ, Lee CS. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis 1986;134:34-8.
32. 32. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: The Organization; 1997. Rep no. WHO/TB/97.220.
33. 33. International Union Against Tuberculosis and Lung Disease/World Health Organization. The promise and the reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994;75:180-1.
34. 34. Kennedy N, Fox R, Kisoyombe GM, Saruni AO, Uiso LO, Ramsay AR, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993;148:1547-51.
35. 35. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisoyombe GM, et al. Randomised controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22:827-33.
36. 36. Yew WW, Kwan SY, Ma WK, Khin MA, Chau PY. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990;26:227-36.
37. 37. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampicin. Tuber Lung Dis 1992;73:59-67.
38. 38. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of gyrA murant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994;170:479-83.
39. 39. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimazadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:4148-50.
40. 40. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997;25:1213-21.
41. 41. US Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42(RR-7):1-8.
42. 42. Clinical policies and protocols, Bureau of Tuberculosis Control, New York City Department of Health. 3rd ed. New York: New York City Department of Health; 1999.
43. 43. Snider DE Jr. Long MW, Cross FS, Farer LS. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Ann Rev Respir Dis 1984;129:573-9.
44. 44. US Public Health Service recommendations for human immunodeficiency virus counseling and resting for pregnant women. MMWR 1995;44(RR-7):1-14.
45. 45. Perriens JH, St. Louis ME, Mukadi YB, Brown C, Prignot J, Gouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;33:8879-84.
46. 46. Carpenter CCJ, Fiscal MA, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997 updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-9.
47. 47. Panel on Clinical Practices for Treatment Infections. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. US Department of Health and Human Services and Henry J. Kaiser Family Foundation; 1997. Available: http://www.hivatis.org/archivedguidelines.html.
48. 48. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of tuberculosis. Am Rev Respir Dis 1986;133:423-30.
49. 49. Canadian tuberculosis standards. 4th ed. Ottawa: Canadian Lung Association; 1996. p. 32-41.